XML 38 R22.htm IDEA: XBRL DOCUMENT v3.8.0.1
Equity
 12 Months Ended
Dec. 31, 2017
Equity [Abstract]  
Equity
Note 14 — Equity
Common Stock
On October 31, 2013, we announced that Ocwen’s Board of Directors had authorized a share repurchase program for an aggregate of up to $500.0 million of Ocwen’s issued and outstanding shares of common stock. This share repurchase program expired on July 31, 2016. During 2016, we completed the repurchase of 991,985 shares of common stock in the open market under this program for a total purchase price of $5.9 million. From inception of this program through expiration, we completed the repurchase of 13,163,793 shares for an aggregate purchase price of $380.3 million.
Ocwen and NRZ entered into a share purchase agreement pursuant to which Ocwen sold NRZ 6,075,510 shares of newly-issued Ocwen common stock for $13.9 million. Ocwen received the sales proceeds from NRZ on July 24, 2017 and issued the shares. The shares have not been registered under the Securities Act of 1933 and were issued and sold in reliance upon the exemption from registration contained in Section 4(a)(2) of the Act and Rule 506(b) promulgated thereunder. See Note 8 — Rights to MSRs for additional information.
Ocwen agreed to issue an aggregate of 2,500,000 shares of common stock in connection with a mediated settlement of litigation. As of December 31, 2017, Ocwen had issued 625,000 shares with the remaining 1,875,000 shares issued in January 2018. The shares have not been registered under the Securities Act of 1933 and were issued in reliance upon the exemption from registration set forth in Section 3(a)(10) of the Act. See Note 24 — Contingencies for additional information.
Accumulated Other Comprehensive Loss
The components of accumulated other comprehensive loss (AOCL), net of income taxes, were as follows:
 
December 31,
 
2017
 
2016
Unrealized losses on cash flow hedges
$
1,128

 
$
1,329

Other
121

 
121

 
$
1,249

 
$
1,450